Skip to main content
. 2014 Oct 17;9(10):e108619. doi: 10.1371/journal.pone.0108619

Figure 4. Analysis of patients negative to rVes v 5 with rVes v 3, rVes v 1 and natural venom, improves the trade-off between sensitivity and specificity of the Basophil activation test.

Figure 4

(A) Percentage of patients positive to basophil activation test performed with natural venom and recombinant allergens. (B) Analysis of patients negative to recombinant Ves v 5 with natural venom and other recombinant allergens. (C) Specificity and sensitivity of natural venom, recombinant Ves v 5 and recombinant Ves v 3 at cut off 15.7% CD63 expression. (D) Specificity and sensitivity of multistep analysis of BAT considering rVes v 5 alone, rVes v 5 plus rVes v 3, and rVes v 5 plus rVes v 3 plus natural venom.